C olorectal cancer is a major American health problem, ranking as the second leading cause of cancer death, after lung cancer, in the United States. About 129,400 new cases are diagnosed each year, and 56,600 Americans die annually from this disorder. 1 The etiology of colorectal cancer is heterogeneous, with environment or genetics playing varying key roles in different patients. 2 About 80% of patients with colorectal cancer seem to have sporadic disease with no evidence of having inherited the disorder. In the remaining 20%, there seems to be a potentially definable genetic component. Evidence for a genetic contribution to colorectal cancer includes increased risk of colorectal malignancy in persons with a family history and familial aggregation of colorectal cancer consistent with autosomal dominant inheritance. 3, 4 In the past decade, germline genetic mutations conferring high lifetime risk of colorectal cancer in carriers have been found, accounting for 5%-6% of all colorectal cancer cases. Other gene mutations, some with lower lifetime risks, are continuing to be characterized.
The translation into clinical practice of genetic discoveries related to hereditary colorectal cancer continues apace, primarily through improved risk assessment by genetic testing. When used appropriately, genetic testing for hereditary forms of colorectal cancer can confirm or reject the diagnosis at the molecular level, justify surveillance of at-risk persons, decrease the cost of surveillance by risk stratification, aid in surgical and chemoprevention management, and help in decisions regarding family and career planning. But when used inappropriately, genetic testing has the potential to misinform affected patients with false-negative results. 5 This technical review critically analyzes currently available literature and: (1) succinctly reviews the known colorectal cancer genetic syndromes of familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) and variants, (2) analyzes the current availability and cost of genetic tests, and (3) describes indications for use of genetic tests in the hereditary colorectal cancer syndromes.
Literature Review

General Information
Study identification and selection. A systematic computer-aided search of MEDLINE and Current Contents from January 1966 to December 1999 was performed focusing on the major hereditary colorectal cancer syndromes and associated reports of genetic testing. The search identified all literature under the medical subject headings and text words, "familial adenomatous polyposis," "adenomatous polyposis," "adenomatous polyposis coli," "familial polyposis coli," "hereditary nonpolyposis colorectal syndrome," "HNPCC," "Lynch syndrome," and "gene/genetic testing." In addition, an extensive manual search was conducted using references from all retrieved reports, review articles, and chapters from gastroenterology textbooks. Data concerning availability and costs of genetic tests were collected by a search of GeneTests, www.genetests.org, and by telephone survey of specific laboratories. Publications and other information were retrieved, and the authors synthesized and assessed the quality of the available data with respect to topicality and currency. Differences among reviewers concerning inclusion were resolved by consensus. Editorials and letters to the editor were excluded from this review. estimated to occur in 1 of 8300 to 1 of 14,025 live births, affects both sexes equally, and has worldwide distribution. 9 Characteristically, teenaged patients develop multiple (Ն100) adenomas diffusely throughout the colon ( Figure 1) ; 50% of FAP patients develop adenomas by 15 years of age and 95% by age 35. 10 -12 Colorectal cancer is inevitable in FAP patients if colectomy is not performed. The average age at diagnosis ranges from 34.5 to 43 years. 10, 13 In addition to polyposis coli, patients with FAP can develop a variety of benign extracolonic manifestations (Table 1) . These include extracolonic polyps (adenomas of the small intestine and stomach, fundic gland retention polyps of the stomach), 14 -17 cutaneous lesions (lipomas, fibromas, sebaceous, and epidermoid cysts), 18, 19 desmoid tumors, 20 osteomas, 21, 22 occult radiopaque jaw lesions, 23 dental abnormalities, 24 pigmented ocular fundic lesions (congenital hypertrophy of the retinal pigment epithelium), 23, 25, 26 and nasopharyngeal angiofibroma. 27 Extracolonic malignancies that can develop in FAP patients include hepatoblastoma, 28 upper gastrointestinal tract malignancies (duodenum and periampullary area, very rarely jejunum), 16 thyroid gland, biliary tree, pancreas, 29 and brain. 30 FAP is also known as familial polyposis, and older terminology designated patients with extraintestinal manifestations as having Gardner syndrome.
Genetic defect. Almost all cases of FAP are caused by germline mutations of the APC gene on chromosome 5q21. 6 -8,31 The APC gene is a tumor suppressor or "gatekeeping" gene with 15 exons that encodes for a 2843 amino acid protein with a molecular weight of 309,000 daltons considered important in cell adhesion, signal transduction, and transcriptional activation. 32 Beta-catenin and c-myc have been identified as downstream targets. 32 More than 300 different mutations of the APC gene causing FAP have been reported. 33 Most are insertions, deletions, and nonsense mutations that lead to frame shifts or premature stop codons, resulting in truncation of the APC gene product. The most common mutation, occurring in 10% of FAP patients, is a deletion of AAAAG in codon 1309.
Genotype-phenotype studies reveal that APC gene mutations between codons 169 -1393 result in classic FAP, more 3Ј and 5Ј mutations predispose to attenuated FAP, 34 -36 and mutation I1307K of the APC gene increases risk of colorectal cancer among persons of Ashkenazi Jewish ancestry 37 (see Attenuated FAP and I1307K APC Gene Mutation). Other correlations with mutation include the profuse colorectal polyposis between codons 1250 and 1464, 38 predilection for multiplicity of extraintestinal manifestations at codons 1465, 1546, and 2621, 39 and occurrence of retinal lesions with mutations restricted to codons 463 to 1444. 39 -42 The tendency for desmoid tumors between codons 1445 and 1578 [41] [42] [43] has been reported, although others have not found this association. 39 However, considerable intraand interfamilial phenotypic variability can occur even in persons with identical genotypic mutations. 44 
Management
Screening. At-risk individuals (first-degree relatives of FAP patients; Figure 2 ) should undergo screening for FAP at ages 10 -12. 12,45 The screening test of choice is genetic testing for mutation of the APC gene (see Indications and Strategy for Genetic Testing). 45, 46 If informative genetic testing cannot be done, at-risk members are advised to pursue endoscopic screening with yearly sigmoidoscopy starting at 12 years old, reducing screening frequency with each subsequent decade. After age 50, patients are advised to follow the American Gastroenterology Association guidelines for screening average-risk patients. 45 Hepatoblastoma occurs in about 1 in 300 persons at risk for FAP under the age of 5 years (1 in 150 APC gene mutation carriers). 28 Because of potential cure by early surgery of an otherwise rapidly fatal tumor, screening with serum alpha-fetoprotein levels and imaging of the liver in children of parents affected with FAP from infancy to 5 years of age may be prudent. 28, 47 Treatment. Colectomy is the recommended therapy to eliminate the development of colorectal cancer in FAP patients. Surgery is usually advised at the time of diagnosis to minimize the risk of malignancy. If patients are in the second decade of life, and adenomas are less than 6 mm and without any villous component, delay to accommodate work and school schedules seems appropriate. 13, 45 Surgical options include subtotal colectomy with ileorectal anastomosis, total proctocolectomy with Brooke ileostomy (or continent ileostomy), and proctocolectomy with mucosal proctectomy and ileoanal pullthrough (with pouch formation). 48 -50 Because colorectal cancer can occur in the rectal segment, 51, 52 most investigators favor the latter 2 procedures.
Postoperative follow-up. Patients with subtotal colectomy require routine endoscopic surveillance of the remaining rectum about every 6 months for recurrent adenomas and/or carcinomas. 51, 52 Although the longterm risk of neoplastic transformation in the ileoanal pouch of patients with restorative proctocolectomies is low, adenomas in the pouch have been reported. In such cases some experts have recommended that endoscopic biopsy surveillance should be considered. 53 Most authorities recommend upper endoscopic surveillance (with biopsy and brushing) of the stomach, duodenum, and periampullary region with front-and/or side-viewing endoscopes every 6 months to 4 years, depending on polyp burden. 16 Annual physical examination of the thyroid is warranted, along with consideration for ultrasonography. 29 The use of oral sulindac or celecoxib (a selective COX-2 inhibitor) to prevent or eliminate polyps in the retained rectum has been shown to be effective in the short term. 54 -56 Although regression of polyps throughout the colon with a selective COX-2 inhibitor has been reported, 56 no authority has advocated the use of these agents for primary treatment of FAP. Sulindac has also been noted in case reports to regress duodenal adenomas, but a small controlled study showed no benefit. 55 
Attenuated FAP
Genotype-phenotype correlation studies have reported that mutations in the 5Ј (5Ј to codon 158) and 3Ј (3Ј to codon 1596) ends of the APC gene are associated with a less severe phenotype of FAP. 34, 35, [57] [58] [59] [60] [61] This variant was first termed attenuated adenomatous polyposis coli (AAPC) by Spirio et al. in 1992 34 and later renamed attenuated familial adenomatous polyposis. 61 The clinical characteristics of the attenuated variant include oligopolyposis (fewer than 100 colorectal adenomas) at presentation but marked phenotypic variation within pedigrees, and a delayed onset of colorectal cancer that occurs on average 12 years later than in classic FAP. 35 In addition, a plethora of upper tract lesions has been noted in some of these patients. 62 
I1307K APC Gene Mutation
Recently, a missense mutation in the APC gene, APC I1307K, was discovered as a cause for an undefined proportion of familial colorectal cancer in patients in a specific ethnic group 37 ; this mutation is found in 6% of the general Ashkenazi Jewish population. 37, 63, 64 Individuals with this mutation have an increased lifetime risk of colorectal cancer, with an estimated odds ratio of 1.4 to 1.9. 37, 63, 64 The mechanism by which the missense mutation predisposes colonic epithelial cells to acquire somatic mutations in the APC gene is through the instability conferred by the thymine to adenine transversion, resulting in a polyadenine tract in the gene. There is an increased frequency of somatic mutations in the mutation-bearing allele in colorectal tumors of I1307K carriers. 37, 63, 64 Genetic testing for the APC I1307K gene mutation is commercially available for Ashkenazi Jewish individuals with a personal or family history of colorectal cancer ( Table 2 ). Further research is ongoing to delineate the clinical application of this mutation and other associated phenotypic characteristics. The results of future investigation will determine the advisability of using APC I1307K testing in clinical management.
HNPCC
Clinical features. In 1966, Dr. Henry Lynch and colleagues described familial aggregation of colorectal cancer with stomach and endometrial tumors in 2 extended kindreds and termed it Cancer Family Syndrome 65 ; later, authors designated this constellation Lynch syndrome. More recently, this condition has been called HNPCC. In HNPCC, unlike FAP, colorectal cancer usually arises from a single colorectal lesion in the absence of polyposis (Ն100 adenomas). 66 -68 HNPCC is an autosomal dominant disorder accounting for about 3%-5% (range, 1%-13%) 69 -71 of all colorectal cancer cases caused by mutation of 1 of the DNA mismatch repair genes. Individuals with an HNPCC gene mutation have approximately a 70%-80% lifetime risk of developing colon or rectal cancer. 72, 73 Colorectal cancer occurs at a younger age (average, 44 years old), compared with sporadic cases of people developing cancer in the seventh decade of life. 68 Colorectal tumors arise primarily (60%-80%) on the right side of the colon (proximal to the splenic flexure); in sporadic colorectal cancer, only 23%-32% are right-sided. 68 In 45% of affected individuals, multiple synchronous and metachronous colorectal cancers can occur within 10 years of resection. 66, 74 The precursor lesion for HNPCC seems to be a discrete proximal colonic adenoma, which can occasionally appear flat rather than polypoid. 75, 76 These lesions are more often villous, with areas of high-grade dysplasia, than those from the general population and consequently are considered more likely to undergo malignant transformation. 77 The histopathology of HNPCC colorectal cancers tends to be poorly differentiated, abundant in extracellular mucin, and distinguished by a lymphoid (Crohn's-like pattern or peritumoral lymphocytes) host response to the tumor. 78, 79 HNPCC patients have improved survival from colorectal cancer stage-for-stage compared with those with sporadic tumors. 80 In addition to colorectal cancer, patients and family members are at jeopardy for a wide variety of extracolonic malignancies ( Table 1 ). The highest risk in HNPCC patients occurs for endometrial and ovarian malignancy (39% and 9% risk by age 70, respectively). [81] [82] [83] [84] Increased relative risk of transitional cell carcinoma of the ureter and renal pelvis and adenocarcinomas of the stomach, small bowel, ovary, and biliary system occurs in these pedigrees (ranging from 3 to 25 times the general population). [81] [82] [83] [84] Also, an excess of pancreas, larynx, breast, brain, and hematopoietic malignancies has been described. 68, 85 Unlike FAP with multiple overt syndromic manifestations, café au lait spots, sebaceous gland tumors, and keratoacanthomas (the latter 2 found in the variant Muir-Torre syndrome) are the only reported phenotypic signs in HNPCC. 85 In 1990, the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer established research criteria (ICG or Amsterdam criteria I) for HNPCC 86 (Table 3 ). All of the following are required to diagnose HNPCC: (1) 3 or more relatives with histologically verified colorectal cancer, 1 of whom is a firstdegree relative of the other 2 (FAP should be excluded); (2) colorectal cancer involving at least 2 generations; (3) 1 or more colorectal cancer cases diagnosed before the age of 50. In response to concern that these standards are too stringent, particularly for clinical application and further research, alternative criteria (Amsterdam criteria II) were proposed (Table 3) . Amsterdam criteria II include extracolonic tumor types commonly observed in HNPCC, such as cancer of the endometrium, upper gastrointestinal tract, and urinary tract. 87 
Genetic Defect
HNPCC is caused by mutation of 1 of several DNA mismatch repair genes. These genes function to maintain fidelity of DNA during replication by correction of nucleotide base mispairs and small insertions or deletions generated by misincorporations or slippage of DNA-polymerase during DNA replication. The mismatch repair genes include hMSH2 (human mutS homolog 2) on chromosome 2p16 88, 89 ; hMLH1 (human mutL homolog 1) on chromosome 3p21 90, 91 ; hPMS1 and hPMS2 (human postmeiotic segregation 1 and 2) on chromosomes 2q31 and 7q11, 92 respectively; and hMSH6 (human mutS homolog 6) on chromosome 2p16. 93, 94 Germline mutations of hMSH2 (frameshift ϭ 60%, or nonsense mutations ϭ 23%) and hMLH1 (frameshift ϭ 40%, and missense alterations ϭ 31%) account for more than 95% of the mutations found in HNPCC families; they are distributed throughout the 16 and 19 exons of these 2 genes, respectively. 95 Microsatellite instability (MSI) is a phenomenon found in the colorectal cancer DNA (but not in the adjacent normal colorectal mucosa) of individuals with mismatch repair gene mutations. MSI is characterized by expansion or contraction of short repeated DNA sequences (i.e., microsatellite repeats) caused by insertion or deletion of repeated units. This instability, known as "mutator phenotype," "replication error," or "microsatellite instability," indicates probable defects in the mismatch repair genes caused by somatic changes or can suggest the diagnosis of HNPCC. 96 MSI has been found in most cases (Ͼ90%) of HNPCC that fulfill the Amsterdam criteria 71 and in 15% of sporadic colorectal cancers. The role of MSI analysis has led to the development of the Bethesda criteria, which set forth clinical indications for use of this assay and standardization of tumor analysis (Tables 4 and 5 ). 70, 97 The Bethesda criteria have been modified in the Medical Position Statement for purposes of genetic testing by changing the guidelines for age of adenocarcinoma diagnosis from less than 45 years old to less than 50 years old. Recently, investigators have found that MSI, as a marker for the mismatch repair pathway of colorectal neoplasia, is asso- 80, 98 In addition, 1 study reported that adjuvant chemotherapy resulted in greater survival benefits for patients with MSI-positive tumors. 99 
Management
Screening. Recommendations for colorectal cancer screening in HNPCC have been published by several authors 45,100 on the basis of expert and consensus opinion. In the absence of genetic testing, first-degree relatives (at 50% risk for HNPCC) of affected individuals are recommended to have colonoscopy every 1-2 years, starting between 20 and 30 years of age, and annually after 40 years of age, 45 or alternatively every 1-2 years, beginning at age 25. 100 Individuals with germline mutations are recommended to start colonoscopy at age 25 or 5 years younger than the youngest age at diagnosis in the family, whichever comes first, and to continue annually. 100 Jarvinen et al. showed that colorectal screening decreases morbidity and mortality from colorectal cancer for the children of patients with HNPCC. 101 Annual screening for endometrial cancer is recommended by expert opinion beginning at age 25-35. There is no consensus on the optimal method of screening, but choices include endometrial aspiration or transvaginal ultrasonography. 68, 102 The efficacy of these tools remains uncertain. 102 Some experts have recommended screening for ovarian and genitourinary cancers when these tumors have been observed in the family, 103, 104 although insufficient data exist to evaluate this strategy. Proposed methods of screening for ovarian cancer include transvaginal ultrasonography and serum CA-125, and urine analysis for renal tumors.
Treatment. Subtotal colectomy with ileorectal anastomosis (and postsurgical rectal surveillance) is recommended when colorectal cancer develops in the setting of HNPCC because of the high rate of metachronous colorectal cancer noted in follow-up studies. 66, 102 This operation can be considered for prophylaxis in selected mismatch repair gene mutation carriers with adenomas at time of surveillance and is an option in mutation carriers without mucosal disease. 102 A consensus panel found insufficient evidence to recommend for or against prophylactic hysterectomy and oophorectomy as a measure for reducing cancer risk 102 and advised that women who are carriers of the HNPCCassociated mutation should be counseled that this is an available option.
Review of Genetic Testing Studies
A detailed literature review of hereditary colorectal cancer genetic testing studies is presented below. Investigators have used a variety of test methodologies to search for mutations in the hereditary colorectal cancer genes. Descriptions of these techniques are presented in the glossary. [105] [106] [107] FAP Studies using various methods for identifying APC gene mutations are noted in Table 6 . Methodologies for FAP gene testing include linkage analysis, which is informative for 33%-80% of FAP pedigrees 108,109 ; single-strand conformation polymorphism testing (SSCP), which has been reported to detect 29% of mutations in the APC gene 110 ; protein truncation testing (PTT), which ranges from 79% to 90% in sensitivity [111] [112] [113] ; and conversion with PTT, which is reported to detect 96% of mutations in the APC gene. 31 Combinations of mutation screening techniques that combine SSCP, denaturing gradient gel electrophoresis, or sequencing in combination with PTT detect 52% to 90% of mutations. 114 -117 Clinical tests available for FAP are shown on Table 9 . Currently, genetic testing using protein truncation is the preferred methodology for FAP gene testing. In contrast to sequencing, which can detect variants of unknown significance, PTT usually detects disease-causing mutations. Also, PTT is generally less costly than sequencing, and turnaround time for results is shorter.
HNPCC
As described above, MSI is a genetic phenomenon found in colorectal tumor DNA. Before 1997, investigators used a variety of markers to show MSI in colorectal cancer specimens. In 1997, the National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome proposed specific markers for MSI testing (Table 5) . 70, 97 Results are classified as MSI-high, MSIlow, or MSS (microsatellite stable), as described in Table  5 . MSI is considered to be present in the specimen if the result is MSI-high.
The occurrence of MSI in various patient populations with colorectal cancer varies, as shown in Table 7 . The majority of these studies were performed before standardization of MSI testing in 1997. The greatest frequency of MSI was found in the tumors of patients who are clinically affected with HNPCC, by Amsterdam criteria. A significant decrement in MSI positivity occurs in all other populations. Compared with sporadic colorectal cancers, in which MSI is noted in 15% of patients, individuals with colorectal cancer at young age, suspected HNPCC, and right-sided colorectal cancer have frequencies of MSI positivity ranging from 17% to 58%. Table 8 summarizes the results of mismatch repair gene testing in several populations at increased risk for colon cancer, using various testing methods. The highest rates of gene mutation were found in families fulfilling the Amsterdam criteria for HNPCC (45%-64%) and in those individuals with colorectal cancer before age 30 and positive MSI in tumor tissue (63%). The range of positivity varied widely, depending on test methodology and number of genes tested. The positivity decreased substantially in those tested from families with suspected HNPCC or those meeting less stringent criteria (0%-47%). A 30% positivity was noted in individuals meeting the Bethesda criteria when analyzing 2 genes (hMLH1, hMSH2), whereas 10% tested positive when hMSH6 alone was analyzed. The occurrence of MSI substantially increased the likelihood of detecting a germline mutation, as noted in individuals with colorectal cancer before the age of 50, and before the age of 30 with and without MSI testing.
Wijnen et al. developed a model for assessing the likelihood of germline mutations in HNPCC. Multivariate analysis showed that a younger age at diagnosis of colorectal cancer, fulfillment of the Amsterdam criteria, and the presence of endometrial carcinoma in the kindred were independent predictors of germline mutations of hMSH2 and hMLH1. 119 Recent research has found that immunohistochemistry (IHC) for hMLH1 and hMSH2 expression is an inexpensive adjunct analysis of colorectal tumors, and when used with MSI can help determine strategies for germline testing. Lack of expression of either hMSH2 or hMLH1 by IHC in tumors is correlated with MSI in the tumor. 120 -122 The majority of MSI observed in sporadic cases seem to be caused by somatic hypermethylation of the hMLH1 promoter. 123, 124 It has also been observed that absent hMSH2 IHC expression is associated with germline hMSH2 mutation, and a minority of absent hMLH1 IHC expression is associated with germline hMLH1 mutation. 124 IHC for these 2 genes is now transitioning into routine clinical practice.
Indications and Strategy for Genetic Testing
Recommendations for the rational use of genetic tests have been published by several organizations. [125] [126] [127] The American Society of Clinical Oncology (ASCO) recommends that practitioners must ensure that the patient or guardian has given informed consent. 125 Experts advise that written informed consent be obtained on test-specific forms. The form should include a general description and purpose of the test, a description of the disorder tested for, the meaning of positive and negative test results, the level of certainty that a positive test result serves as a predictor for the disease, and the actions that persons can take if they receive a positive result. In addition, ASCO advocates that practitioners include pre-and post-test genetic counseling about the possible risks and benefits of early detection of cancer and of prevention modalities with presumed but unproven efficacy for individuals at the highest risk for cancer. Among concerns addressed by counseling in genepositive patients include anger and denial about the test result, worry about social stigma, greater trepidation of surgery or death, anxiety about interference with work or school, and fear of loss of insurability. Gene-negative patients can develop "survivor guilt"- DGGE, Denaturing gradient gel electrophoresis; RT-PCR, reverse-transcription polymerase chain reaction; CRC, colorectal cancer. a HNPCC suspected is based on family history, but criteria were not specified.
guilt over escaping an illness that has afflicted other family members. Counseling issues are further explored in other publications. 125, 128, 129 In general, genetic testing should be offered only when: (1) the person has a strong family history of cancer or early age of onset of the disease, (2) the test can be adequately interpreted, and (3) the results will influence the medical management of the patient or family member. 125 
FAP
Genetic testing in FAP is considered the standard of care for management of this disorder. 100, 125 APC gene testing. Concordant indications for APC gene testing have been developed by several organizations 45, 100 and by expert opinion. 12, 46 These include confirmation of the diagnosis of FAP and presymptomatic diagnosis of individuals 10 years of age or older at risk for FAP (first-degree relatives of those affected) (Table 9, Figure 2) .
The strategy for testing of individuals affected and at risk for FAP (presymptomatic testing) is illustrated in Figure 1 of the adjoining Medical Position Statement. 12,46,100 Evaluation of at-risk persons begins by first testing an affected member of the family to establish a detectable mutation in the pedigree. Several methods for APC gene testing are commercially available, as shown in Table 2 . Although sequencing provides a high degree of sensitivity for mutations in the APC gene, the protein truncation test is less labor intensive and has the advantage of selecting for disease-causing mutations. Protein truncation testing is also preferred over linkage analysis because only 1 affected family member is required for PTT. In individuals affected with FAP, PTT detects 80% of mutations in the APC gene. Future introduction of conversion technology may increase the sensitivity to 96%. 31, 130 If a mutation is found in an affected family member, then genetic testing in at-risk relatives will provide true positive or negative results. Appropriate screening strategies can then be undertaken, based on the at-risk person's gene test result. If a mutation is not identified, testing at-risk relatives is useless because the gene test will be inconclusive: a negative result could be a false negative because the PTT is not capable of detecting a mutation, even if present. When an affected family member is not available for evaluation, performing the test on at-risk family members can provide only positive or inconclusive results. In this circumstance, a true negative test result for an at-risk individual can only be inferred if another at-risk family member tests positive for a mutation.
Attenuated FAP
Experts agree that APC testing is indicated for confirmational and presymptomatic diagnosis in attenuated FAP, but no clear standard exists concerning the number of colorectal adenomas needed to suspect this diagnosis in the index case. Some experts would test patients with 20 or more cumulative colorectal adenomas. 5 
HNPCC
Medical benefit of genetic testing in HNPCC is presumed but has not been established. 125 MSI testing. MSI evaluation is indicated for patients who meet the Bethesda criteria modified, as noted in Table 4 . 70 MSI testing of the colorectal tumor (adenocarcinoma or adenoma) serves as a screening test for HNPCC (Table  2) . Evaluation for MSI is suggested by consensus panel 100 and expert opinion 128, 129 as the first step in the genetic work-up of pedigrees suspected to be affected by HNPCC (Figure 2 of the adjoining Medical Position Statement). MSI testing is performed on the tumor tissue of individuals putatively affected with HNPCC. A result of MSI-high in tumor DNA provides evidence for the presence of germline mutation in a mismatch repair gene and prompts patient testing for mutation of the hMSH2 and hMLH1 genes (commercial analysis is only available for mutations in these 2 genes). Individuals with MSIlow or MSS tumors are unlikely to harbor germline mismatch repair gene mutations, and further genetic work-up can be suspended. In families in which tumor tissue is not available, consideration can be given to (Table 9 ). This strategy for use of MMR gene testing has been espoused by a consensus panel 100 and expert opinion. 128, 129 Currently, commercial analysis is only available for mutations in hMSH2 and hMLH1. Genetic testing is offered to individuals putatively affected with HNPCC whose tumor tissue has tested MSIhigh ( Figure 2 of the adjoining Medical Position Statement). Table 2 describes methods of testing for mutations of the mismatch repair genes. Although protein truncation testing is preferred for FAP, PTT has lower sensitivity for mutations in the mismatch repair genes. Therefore, sequencing, CSGE, or SSCP is favored for MMR gene testing. Future introduction of conversion technology may increase the sensitivity for detection of MMR gene mutations to 96%. 31, 130 If a mutation is found in an affected family member, then genetic testing in at-risk relatives will provide true positive or negative results. Appropriate screening strategies can then be undertaken based on the at-risk person's gene test result. If a pedigree mutation is not identified, further testing of at-risk relatives is suspended because any negative gene test will be inconclusive. Such a result could be a false negative because the analysis is not capable of detecting a mutation even if present, or a disease-causing mutation may be present in other known MMR genes, or in yet undiscovered genes.
When an affected family member is not available for evaluation, starting the testing process with at-risk family members can provide only positive or inconclusive results. In this circumstance, a true negative test result in an at-risk individual can only be obtained if another at-risk family member tests positive for a mutation. This strategy is not preferred because of the high likelihood of inconclusive test results. 
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